Accession Therapeutics Limited
Accession Therapeutics is a biotech company focused on developing novel immune-oncology therapeutics using its proprietary Trocept platform technology. Led by pioneer Bent Jakobsen, the company aims to create highly specific, broad in action, and potent cancer treatments by engineering viruses that target cancer cells and carry therapeutic transgenes. The company is progressing its pipeline towards clinical trials, with its first drug candidate in Phase 1, and is backed by international investors including Primavera Venture Partners, Birk Venture, and iGlobe Partners.
Industries
Nr. of Employees
small (1-50)
Accession Therapeutics Limited
Building 7600, The Quorum, Alec Issigonis Way, ARC Oxford North, OX4 2JZ
Products
Tumour-activated oncolytic viral immunotherapy (lead candidate)
A systemically administered, tumour-selective viral vector that replicates in cancer cells and encodes a therapeutic transgene to be produced locally within tumours (lead programme progressed to Phase 1–2 master protocol).
Platform-derived therapeutic candidates (pipeline)
Pipeline of tumour-targeted viral candidates carrying diverse payloads (for example checkpoint inhibitor transgenes and bispecific immune activators) at preclinical and IND-enabling stages.
Tumour-activated oncolytic viral immunotherapy (lead candidate)
A systemically administered, tumour-selective viral vector that replicates in cancer cells and encodes a therapeutic transgene to be produced locally within tumours (lead programme progressed to Phase 1–2 master protocol).
Platform-derived therapeutic candidates (pipeline)
Pipeline of tumour-targeted viral candidates carrying diverse payloads (for example checkpoint inhibitor transgenes and bispecific immune activators) at preclinical and IND-enabling stages.
Services
Partnering for co-development, licensing or collaboration around a tumour-targeted viral vector platform at IND or early clinical stage.
Sponsorship and operational delivery of Phase 1/2 master-protocol clinical studies for systemically administered tumour-targeted viral therapeutics.
Partnering for co-development, licensing or collaboration around a tumour-targeted viral vector platform at IND or early clinical stage.
Sponsorship and operational delivery of Phase 1/2 master-protocol clinical studies for systemically administered tumour-targeted viral therapeutics.
Expertise Areas
- Immuno-oncology
- Viral vector design and tropism modification
- Oncolytic virotherapy
- Transgene-encoded local therapeutics
Key Technologies
- Adenoviral vector engineering
- Integrin-directed targeting
- Oncolytic viral replication
- Intravenous systemic viral delivery
News & Updates
Accession Therapeutics has received approval to start its first clinical trial in cancer patients for TROCEPT-01, a novel immunotherapy platform, in the UK. The trial is a milestone reached just over three years since inception.
An article profiling Accession Therapeutics as a biotech developing precisely targeted oncolytic viruses using its Trocept platform.
Accession Therapeutics has received approval to start its first clinical trial in cancer patients for TROCEPT-01, a novel immunotherapy platform, in the UK. The trial is a milestone reached just over three years since inception.
An article profiling Accession Therapeutics as a biotech developing precisely targeted oncolytic viruses using its Trocept platform.